目的 探讨高强度聚焦超声(HIFU)治疗乳腺癌的有效性和可行性.方法 选取经穿刺活检病理确诊为乳腺浸润性导管癌患者13例,接受高强度聚焦超声治疗而后行改良根治术,对癌组织及周围正常组织分别取材,进行光镜、电镜观察及NADH-黄递酶活性检测.结果 光镜观察11例靶区内肿瘤组织仅有轻微退变,2例靶区内约40％的肿瘤组织出现凝固性坏死.电镜显示靶区内肿瘤细胞凝固性坏死,NADH-黄递酶活性检测发现靶区肿瘤染色阴性.结论 经高强度聚焦超声治疗,乳腺癌组织发生坏死,HIFU有望成为乳腺癌治疗的有效方法.

OBJECTIVE:To analyze the clinical pathological features and relativity of breast benign diseases and breast cancer.METHODS:The clinical pathological data of 2 222 cases of breast benign diseases and breast cancer were analysed retrospectively,and the ER expression in breast cancer's adjacent tissue was examined.RESULTS:A total of 94.8% of all breast benign diseases were proliferative breast diseases;95.8% of all malignant cases were infiltrating cancer.The average age(47.1)of breast cancer was higher than that(34.9)of proliferative breast diseases,P0.000 1.The breast cancer risk for the patients with malignant family history was higher than that for those without malignant family history,P0.001.Seventy-two percent of proliferative breast diseases appeared simultaneously more than three pathological elements.The incidence rate of AH in breast cancer adjacent tissue(23.5%)was much higher than that in pure proliferative breast lesion process(2.49%),P0.01.ER appeared high expression in breast cancer and various lesions of breast cancer adjacent tissue.CONCLUSION:Proliferative breast disease is the most common breast benign disease with multi-lessions,and its process is related to breast cancer.

OBJECTIVE:To detect the changes and implication of multi-biological markers in the different precancerous lesions of breast.METHODS: The expressions of ER,PR,pS2,p53, C-erbB-2 in breast normal tissue, hyperplasia, atypical hyperplasia and early-stage breast cancer were examed by the immunohistochemical technique. RESULTS: The expressions of ER and PR were related to the breast proliferative degree (r=0.446, P0.0001; r=0.363, P 0.000 1) ; the positive expression rates of ER and PR in atypical hyperplasia were 64.4% and 73.3% respectively, significantly higher than those in normal breast tissue (11.5% and 15.4% respectively) and in hyperplasia (22% and 28% respectively). The expression rates of pS2, p53, c-erbB-2 were relative low in the different precancerous lesions. The co-expressions with 2 markers or more were found in 68.9% atypical hyperplasia, significantly higher than those in normal breast (3.8%,P0.01) and in hyperplasia(14%,P0.01). CONCLUSION: ER and PR are important factors to promote breast hyperplasia advance and carcinogenesis, and the co-expressions of multi-biological markers are significantly accumulated in precancerous lesions.